Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
57
FMS Quote, Financials, Valuation and Earnings
Last price:
$22.75
Seasonality move
:
2.45%
Day range:
$22.81 - $23.20
52-week range:
$22.05 - $30.46
Dividend yield:
3.57%
P/E ratio:
16.58x
P/S ratio:
0.62x
P/B ratio:
0.88x
Volume:
500.8K
Avg. volume:
423.9K
1-year change:
0.75%
Market cap:
$13.4B
Revenue:
$20.9B
EPS (TTM):
$1.38
Analysts' Opinion
-
Consensus RatingFresenius Medical Care AG has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 3 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $28.51, Fresenius Medical Care AG has an estimated upside of 25.61% from its current price of $22.85.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $19.98 representing 100% downside risk from its current price of $22.85.
Fair Value
-
According to the consensus of 5 analysts, Fresenius Medical Care AG has 25.61% upside to fair value with a price target of $28.51 per share.
FMS vs. S&P 500
-
Over the past 5 trading days, Fresenius Medical Care AG has underperformed the S&P 500 by -5.22% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Fresenius Medical Care AG does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Fresenius Medical Care AG has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Fresenius Medical Care AG reported revenues of $5.7B.
Earnings Growth
-
Fresenius Medical Care AG has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Fresenius Medical Care AG reported earnings per share of $0.55.
Enterprise value:
25.4B
EV / Invested capital:
--
Price / LTM sales:
0.62x
EV / EBIT:
12.99x
EV / Revenue:
1.17x
PEG ratio (5yr expected):
1.26x
EV / Free cash flow:
12.70x
Price / Operating cash flow:
6.70x
Enterprise value / EBITDA:
6.87x
Gross Profit (TTM):
$5.4B
Return On Assets:
2.83%
Net Income Margin (TTM):
4.69%
Return On Equity:
6.14%
Return On Invested Capital:
3.54%
Operating Margin:
10.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $20.8B | $20.9B | $21.7B | $5.2B | $5.7B | |
| Gross Profit | $5.2B | $5.2B | $5.4B | $1.3B | $1.5B | |
| Operating Income | $1.6B | $1.8B | $2B | $377.5M | $582M | |
| EBITDA | $3.5B | $3.4B | $3.7B | $786.2M | $1B | |
| Diluted EPS | $0.82 | $1.22 | $1.38 | $0.40 | $0.55 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $9.3B | $8.3B | $9.6B | $9B | $9.2B | |
| Total Assets | $39.2B | $37.6B | $37.7B | $36.3B | $36.3B | |
| Current Liabilities | $8.7B | $6.2B | $7B | $6.6B | $6.8B | |
| Total Liabilities | $23.6B | $21.2B | $21.4B | $19.8B | $19.9B | |
| Total Equity | $15.6B | $16.4B | $16.3B | $16.5B | $16.3B | |
| Total Debt | $13.7B | $12.9B | $13.2B | $12.4B | $12.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.7B | $2.5B | $2.8B | $1.1B | $872.6M | |
| Cash From Investing | -$656.9M | -$37.5M | -$441.3M | -$233.9M | -$61.6M | |
| Cash From Financing | -$1.4B | -$2.6B | -$2.4B | -$529.4M | -$1.3B | |
| Free Cash Flow | $1.9B | $1.7B | $2B | $878.7M | $661M | |
FMS
Sector
Market Cap
$13.4B
$28.8M
Price % of 52-Week High
75.02%
52.28%
Dividend Yield
3.57%
0%
Shareholder Yield
4.57%
-1.55%
1-Year Price Total Return
0.75%
-18.69%
Beta (5-Year)
0.907
0.497
Dividend yield:
3.57%
Annualized payout:
$0.64
Payout ratio:
-50.14%
Growth streak:
1 years
Technicals
8-day SMA
Sell
Level
$23.76
200-day SMA
Sell
Level
$25.72
Bollinger Bands (100)
Sell
Level
23.56 - 26.34
Chaikin Money Flow
Buy
Level
93.7M
20-day SMA
Sell
Level
$23.59
Relative Strength Index (RSI14)
Sell
Level
35.20
ADX Line
Sell
Level
17.37
Williams %R
Buy
Level
-96.9463
50-day SMA
Sell
Level
$24.07
MACD (12, 26)
Sell
Level
-0.11
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
14.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.7501)
Sell
CA Score
(Annual)
Level (-0.3961)
Buy
Beneish M-Score
(Annual)
Level (-2.7773)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.959)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.
Stock Forecast FAQ
In the current month, FMS has received 1 Buy ratings 3 Hold ratings, and 1 Sell ratings. The FMS average analyst price target in the past 3 months is $28.51.
-
Where Will Fresenius Medical Care AG Stock Be In 1 Year?
According to analysts, the consensus estimate is that Fresenius Medical Care AG share price will rise to $28.51 per share over the next 12 months.
-
What Do Analysts Say About Fresenius Medical Care AG?
Analysts are divided on their view about Fresenius Medical Care AG share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Fresenius Medical Care AG is a Sell and believe this share price will drop from its current level to $19.98.
-
What Is Fresenius Medical Care AG's Price Target?
The price target for Fresenius Medical Care AG over the next 1-year time period is forecast to be $28.51 according to 5 Wall Street analysts, 1 of them rates the stock a Buy, 1 rates the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is FMS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Fresenius Medical Care AG is a Hold. 3 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of FMS?
You can purchase shares of Fresenius Medical Care AG via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Fresenius Medical Care AG shares.
-
What Is The Fresenius Medical Care AG Share Price Today?
Fresenius Medical Care AG was last trading at $22.75 per share. This represents the most recent stock quote for Fresenius Medical Care AG. Yesterday, Fresenius Medical Care AG closed at $22.85 per share.
-
How To Buy Fresenius Medical Care AG Stock Online?
In order to purchase Fresenius Medical Care AG stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get FMS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
FMS
Sector
P/E ratio
16.58x
24.20x
PEG ratio
1.26x
-0.01x
P/B ratio
0.88x
1.84x
Price / LTM sales
0.62x
1.60x
Growth Metrics
FMS
Sector
Revenue growth
9.16%
4.62%
Earnings growth
37.84%
10.88%
Revenue (5-year growth)
1.35%
6.45%
Earnings forecast
$0.62
-$0.19
Profitability
FMS
Sector
Profitability FY 2024
$5.2B
$3.6M
Return on invested capital
3.54%
-32.02%
Return on assets
2.83%
-28.31%
Return on equity
6.14%
-38%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Feb
3
Balance Sheet
FMS
Sector
Total cash
$1.5B
$26.1M
Short term investments
$307.6M
$25.7M
Total assets
$34.8B
$76.6M
Long term debt
$12.2B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
70
RGC alert for Jan 8
Regencell Bioscience Holdings Ltd. [RGC] is down 21.5% over the past day.
Buy
64
RVMD alert for Jan 8
Revolution Medicines, Inc. [RVMD] is up 4.61% over the past day.
Sell
38
CRNX alert for Jan 8
Crinetics Pharmaceuticals, Inc. [CRNX] is down 0.23% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
